RE: Pfizer's Avelumab Javelin Chemotherapy Medley Trial B9991023: A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies

Dear Study Participant:

Welcome to the B9991023 Javelin Chemotherapy Medley study! The purpose of this study is to determine if treating cancer patients with a combination of anti-cancer drugs – each of which works against cancer cells in a different way – may be more effective than treating cancer patients with a single type of anti-cancer drug.

In addition to welcoming you to the trial, we would like to take this opportunity to thank you for your interest in being a part of Pfizer’s efforts to better understand how immunotherapy works against various cancers and how this type of therapy works when combined with other drugs. We thank you in advance for the time and energy that you will devote to receiving therapy and to participating in study visits. And we thank you for the confidence that you place in Pfizer and in the Pfizer team who will be conducting this trial.

As you participate in this trial, if you have any study-related questions, please contact your study doctor ___________ (phone number). The Pfizer study team will stay in very close contact with your study doctor to monitor study progress.

Once again, welcome and thank you.

Sincerely,

The B9991023 Study Team